Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Leber's congenital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood. One form of the disease, LCA2, is caused by mutations in the retinal pigment epithelium-specific 65-kDa protein gene (RPE65). We investigated the safety of subretinal delivery of a recombinant adeno-associated virus (AAV) carrying RPE65 complementary DNA (cDNA) (ClinicalTrials.gov number, NCT00516477 [ClinicalTrials.gov]). Three patients with LCA2 had an acceptable local and systemic adverse-event profile after delivery of AAV2.hRPE65v2. Each patient had a modest improvement in measures of retinal function on subjective tests of visual acuity. In one patient, an asymptomatic macular hole developed, and although the occurrence was considered to be an adverse event, the patient had some return of retinal function. Although the follow-up was very short and normal vision was not achieved, this study provides the basis for further gene therapy studies in patients with LCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.4,87,88”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [88]
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [40]
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [42]
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationIdiopathic Senile Macular Hole: Its Early Stages and Pathogenesis
Gass, J. D. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130683026 · Cited by 992
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Self-citationMutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationRpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Self-citationNatural Course of Retinitis Pigmentosa Over a Three-Year Interval
Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G., & Hanson, A. H. (1985) · American Journal of Ophthalmology · doi:10.1016/0002-9394(85)90351-4 · Cited by 321
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citation
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Aguirre GD, 1998, Mol Vis, 4, 23
- 10.1038/88327 · DOI
- Fosnaugh JS, 1992, Methods Find Exp Clin Pharmacol, 14, 545
Cited by
Items 901–1,000 of 1,031
Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
Igoe, J., Lam, B. L., & Gregori, N. Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185512 · Cited by 36
Ovando-Roche, P., Georgiadis, A., Smith, A. J., Pearson, R. A., & Ali, R. R. (2017) · Current Stem Cell Reports · doi:10.1007/s40778-017-0078-4 · Cited by 39
Choroideremia: molecular mechanisms and development of AAV gene therapy
Patrício, M. I., Barnard, A. R., Xue, K., & MacLaren, R. E. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1484448 · Cited by 35
“This is the same promoter used in two of the LCA clinical trials [70,71].”
Noncoding RNAs in the Regulatory Network of Hypertension
Wu, G., José, P. A., & Zeng, C. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11126 · Cited by 33
Lee, D., Liu, J., Junn, H. J., Lee, E., Jeong, K.-S., & Seol, D. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0334-z · Cited by 47
Xiang, Z., Kuranda, K., Quinn, W. J., Chekaoui, A., Ambrose, R., Hasanpourghadi, M., Novikov, M., Newman, D., Cole, C., Zhou, X., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.258 · Cited by 37
Self-citationRegulation of phagocytosis by TAM receptors and their ligands
Lu, Q., Li, Q., & Lu, Q. (2010) · Frontiers in Biology · doi:10.1007/s11515-010-0034-5 · Cited by 33
“…has recently been successfully used to safely restore vision in patients with an inherited retinal degeneration called leber congenital amaurosis (LCA) (Maguire et al., 2008), which potentially creates a new therapeutic method for rescue of the photoreceptor loss in Mertk deficiency patients.”
BackgroundCao, H., Yang, T., Li, X.-F., Wu, J., Duan, C., Coates, A. L., & Hu, J. (2010) · Gene Therapy · doi:10.1038/gt.2010.125 · Cited by 38
Gene Delivery of a Viral Anti-Inflammatory Protein to Combat Ocular Inflammation
Ildefonso, C. J., Jaime, H., Rahman, M. M., Li, Q., Boye, S. L., Hauswirth, W. W., Lucas, A., McFadden, G., & Lewin, A. S. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.089 · Cited by 33
Delivery of anti-angiogenic molecular therapies for retinal disease
Anderson, O. A., Bainbridge, J. W., & Shima, D. T. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.004 · Cited by 42
Preliminary Results of Gene Therapy for Retinal Degeneration
Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejme0803081 · Cited by 34
Testa, F., Bacci, G. M., Falsini, B., Iarossi, G., Melillo, P., Mucciolo, D. P., Murro, V., Salvetti, A. P., Sodi, A., Staurenghi, G., et al. (2024) · Eye · doi:10.1038/s41433-024-03065-6 · Cited by 40
“Finally, the increased interest in patient-reported outcomes and the need for functional tests encouraged the assessment of patient perspective [44, 45].”
BackgroundInfluentialSelf-citationBlack, A., Vasireddy, V., Chung, D. C., Maguire, A. M., Gaddameedi, R., Tolmachova, T., Seabra, M., & Bennett, J. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2768 · Cited by 32
“27 models for different retinal diseases (91-92) and the retina was one of the first organs in which gene therapy was found to be successful in humans (74, 76, 80, 92-94).”
BackgroundSelf-citationHuman Induced Pluripotent Stem Cells As a Tool to Model a Form of Leber Congenital Amaurosis
Lustremant, C., Habeler, W., Plancheron, A., Goureau, O., Grenot, L., de la Grange, P., Audo, I. S., Nandrot, E. F., & Monville, C. (2013) · Cellular Reprogramming · doi:10.1089/cell.2012.0076 · Cited by 36
Emerging Gene Therapies for Retinal Degenerations
Cepko, C. L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0295-12.2012 · Cited by 35
“For more information, see http://www.jneurosci.org/misc/ifa_minireviews.dtl.”
Duan, Y., Ma, G., Huang, X., D'Amore, P. A., Zhang, F., & Lei, H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.729467 · Cited by 34
“Because the ultimate goal of this research is to explore a novel therapeutic approach to PVR, and AAVs do not cause any disease (33), we chose AAV-derived viral vectors to deliver CRISPR/Cas9 into our target cells.”
Da Costa, R., Röger, C., Segelken, J., Barben, M., Grimm, C., & Neidhardt, J. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19701 · Cited by 32
Torriano, S., Erkilic, N., Baux, D., Cereso, N., DeLuca, V. J., Meunier, I., Moosajee, M., Roux, A., Hamel, C., & Kalatzis, V. (2018) · Scientific Reports · doi:10.1038/s41598-018-26481-7 · Cited by 37
Wood, E. H., Tang, P. H., la Huerta, I. D., Korot, E., Muscat, S. P., Palanker, D., & Williams, G. A. (2019) · Retina · doi:10.1097/iae.0000000000002449 · Cited by 38
Targeting of the NRL Pathway as a Therapeutic Strategy to Treat Retinitis Pigmentosa
Moore, S. M., Skowronska‐Krawczyk, D., & Chao, D. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072224 · Cited by 31
“Clinical trials delivering an adeno-associated viral vector (AAV) containing the wild-type human RPE65 cDNA in patients with RPE65-associated Leber’s Congenital Amaurosis have demonstrated long term improvement in visual function [23,24].”
MethodLaser Photocoagulation Enhances Adeno-Associated Viral Vector Transduction of Mouse Retina
Lee, S. H., Colosi, P., Lee, H., Ohn, Y.-H., Kim, S.-W., Kwak, H. W., & Park, T. K. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.089 · Cited by 35
“Clinical successes with adeno-associated viral (AAV) vectors designed to treat Leber congenital amaurosis suggest that AAV vectors may be a platform technology for a variety of ocular therapeutics (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008).”
BackgroundGrabe, H., Bapuraj, J. R., Wesolowski, J. R., Parmar, H. A., & Trobe, J. D. (2011) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e318223d0a9 · Cited by 32
Pupillometric analysis for assessment of gene therapy in Leber Congenital Amaurosis patients
Melillo, P., Pecchia, L., Testa, F., Rossi, S., Bennett, J., & Simonelli, F. (2012) · BioMedical Engineering OnLine · doi:10.1186/1475-925x-11-40 · Cited by 38
“However, electroretinogram was unable to show the improvements achieved by gene therapy, as it was unrecordable both before and after treatment [8, 11, 12].”
BackgroundMethodResultInfluentialSelf-citationJacobson, S. G., Alemán, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S., Windsor, E. A. M., Świder, M., Herrera, W., & Stone, E. M. (2009) · PubMed Central · Cited by 36
Self-citationCollison, F. T., Park, J. C., Fishman, G. A., McAnany, J. J., & Stone, E. M. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17467 · Cited by 34
Self-citationWiley, L. A., Burnight, E. R., Drack, A. V., Banach, B. B., Ochoa, D., Cranston, C. M., Madumba, R. A., East, J. S., Mullins, R. F., Stone, E. M., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.049 · Cited by 37
“Likewise, improvement in visual acuity, pupillary light reflex, visual fields, and ambulatory vision was detected as early as 2 weeks postinjection and was closely correlated with the area of the retina that received treatment.(11) No adverse immune responses or extraocular spread of AAV2-RPE65 was detected.”
BackgroundMethodResultInfluentialSelf-citationEffects of Topical Brinzolamide on Infantile Nystagmus Syndrome Waveforms: Eyedrops for Nystagmus
Dell’Osso, L. F., Hertle, R. W., Leigh, R. J., Jacobs, J. B., King, S., & Yaniglos, S. S. (2011) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e3182236427 · Cited by 32
Self-citationVliet, K. V., Mohiuddin, Y., McClung, S. H., Blouin, V., Rolling, F., Moullier, P., Agbandje‐McKenna, M., & Snyder, R. O. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2009.03.020 · Cited by 35
Gene therapy then and now: A look back at changes in the field over the past 25 years
Wang, D., Stevens, G., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.040 · Cited by 37
A synthetic opsin restores vision in patients with severe retinal degeneration
Mohanty, S. K., Mahapatra, S., Batabyal, S., Carlson, M. E., Kanungo, G., Ayyagari, A. L., Tchedre, K. T., Franco, J. A., Singer, M. A., Barone, S. B., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.031 · Cited by 43
Yamamoto, S., Sugawara, T., Murakami, A., Nakazawa, M., Nao‐i, N., Machida, S., Wada, Y., Mashima, Y., & Myake, Y. (2012) · Ophthalmology and Therapy · doi:10.1007/s40123-012-0005-9 · Cited by 35
“The results of two clinical studies with RPE65 gene replacement showed that there was improvement of visual acuity and retinal sensitivity in patients with Leber’s congenital amaurosis [10, 11].”
ResultStem cell biology and cell transplantation therapy in the retina
Osakada, F., Hirami, Y., & Takahashi, M. (2009) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-26-297 · Cited by 31
Selot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
“An exception to this is AAV mediated ocular gene transfer, where relatively low doses of vectors are efficient and the immune privileged status of the eye reduces the risk of immune response as shown during RPE65 gene transfer in non-human primates or in humans [13-15].”
Tanaka, N., Dutrow, E. V., Miyadera, K., Delemotte, L., MacDermaid, C. M., Reinstein, S. L., Crumley, W. R., Dixon, C. J., Casal, M. L., Klein, M. L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138943 · Cited by 35
Voretigene Neparvovec and Gene Therapy for Leber’s Congenital Amaurosis: Review of Evidence to Date
Padhy, S. K., Takkar, B., Narayanan, R., Venkatesh, P., & Jalali, S. (2020) · The Application of Clinical Genetics · doi:10.2147/tacg.s230720 · Cited by 39
Development of gene therapy for treatment of age‐related macular degeneration
Askou, A. L. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12452 · Cited by 36
“Adaptive humoural response to the transgene, as well as adaptive cellular response to the AAV2 capsid and to the transgene, was negative (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008, 2009).”
BackgroundGucy2f zebrafish knockdown – a model for Gucy2d-related leber congenital amaurosis
Stiebel‐Kalish, H., Reich, E., Rainy, N., Vatine, G. D., Nisgav, Y., Tovar, A., Gothilf, Y., & Bach, M. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.10 · Cited by 34
Novel RPE65 mutations associated with Leber congenital amaurosis in Chinese patients.
Xu, F., Dong, Q. G., Liu, L., Li, H., Liang, X., Jiang, R., Sui, R., & Dong, F. (2012) · PubMed Central · Cited by 31
Neuoroprotective efficacies by KUS121, a VCP modulator, on animal models of retinal degeneration
Hasegawa, T., Muraoka, Y., Ikeda, H. O., Tsuruyama, T., Kondo, M., Terasaki, H., Kakizuka, A., & Yoshimura, N. (2016) · Scientific Reports · doi:10.1038/srep31184 · Cited by 32
Kelbsch, C., Maeda, F., Lisowska, J., Lisowski, Ł., Straßer, T., Stingl, K. T., Wilhelm, B., Wilhelm, H. M., & Peters, T. M. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13259 · Cited by 34
“…in the development of retinal implants (Asher et al. 2007; Zrenner et al. 2011; Stingl et al. 2013; Ho et al. 2015) and in gene therapy projects (Maguire et al. 2008; Bennett et al. 2012; MacLaren et al. 2014) with the aim of restoring vision in blind or visually impaired patients with severe…”
BackgroundGene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A
Lopes, V. S., & Williams, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017319 · Cited by 35
“In these studies, AAV was used to deliver normal RPE65 cDNA to the RPE cells, and the safety and efficacy of this treatment has now been shown independently in various clinical trials (Bainbridge et al. 2008; Cideciyan et al. 2008, 2009; Hauswirth et al. 2008; Maguire et al. 2008; Jacobson et al. 2012; Testa et al. 20…”
MethodCehajic-Kapetanovic, J., Milosavljevic, N., Bedford, R. A., Lucas, R. J., & Bishop, P. N. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.002 · Cited by 30
Gene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
RPE65 Mutations in Two Japanese Families with Leber Congenital Amaurosis
Katagiri, S., Hayashi, T., Kondo, M., Tsukitome, H., Yoshitake, K., Akahori, M., Ikeo, K., Tsuneoka, H., & Iwata, T. (2014) · Ophthalmic Genetics · doi:10.3109/13816810.2014.991931 · Cited by 30
Gene replacement therapy for retinal CNG channelopathies
Schön, C., Biel, M., & Michalakis, S. (2013) · Molecular Genetics and Genomics · doi:10.1007/s00438-013-0766-4 · Cited by 34
Torriano, S., Erkilic, N., Faugère, V., Damodar, K., Hamel, C., Roux, A., & Kalatzis, V. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx244 · Cited by 30
Du, S.-C., Ou, H., Cui, R., Jiang, N., Zhang, M., Li, X.-R., Ma, J., Zhang, J., & Ma, D. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.072 · Cited by 25
Self-citationNuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00287-1 · Cited by 29
Gene therapy for inherited metabolic diseases
Yılmaz, B. Ş., Gurung, S., Perocheau, D. P. B., Counsell, J. R., & Baruteau, J. (2020) · PubMed Central · doi:10.34763/jmotherandchild.20202402si.2004.000009 · Cited by 39
Gene and cell therapy based treatment strategies for inflammatory bowel diseases
van der Marel, S., Majowicz, A., van Deventer, S., Petry, H., Hommes, D. W., & Ferreira, V. (2011) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v2.i6.114 · Cited by 32
Boye, S. E., Huang, W.-C., Roman, A. J., Sumaroka, A., Boye, S. L., Ryals, R. C., Olivares, M. B., Ruan, Q., Tucker, B. A., Stone, E. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092928 · Cited by 30
Self-citationHagen, S. H., Baumann, T., Wagner, H. J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K. M., & Müller, K. M. (2014) · Scientific Reports · doi:10.1038/srep03759 · Cited by 38
Rescue from Light-Induced Retinal Degeneration by Human Fetal Retinal Transplantation in Minipigs
Li, S. Y., Yin, Z. Q., Chen, S. J., Chen, L.-F., & Liu, Y. (2009) · Current Eye Research · doi:10.1080/02713680902936148 · Cited by 33
THE NATURAL HISTORY OF FULL-FIELD STIMULUS THRESHOLD DECLINE IN CHOROIDEREMIA
Dimopoulos, I. S., Freund, P. R., Knowles, J. A., & MacDonald, I. M. (2017) · Retina · doi:10.1097/iae.0000000000001764 · Cited by 31
Effective and Sustained Delivery of Hydrophobic Retinoids to Photoreceptors
Tang, P. H., Fan, J., Goletz, P. W., Wheless, L., & Crouch, R. K. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5766 · Cited by 29
“The development of therapeutics such as gene therapy and pharmacologic agents aimed at treating LCA2 patients with RPE65 gene mutations has been greatly aided by the availability of animal models.(11,12) Mouse cones contain two visual pigments that, when bound to 11-cis retinal, are sensitive to either short-wavelengt…”
BackgroundNojima, S., Toyofuku, T., Kamao, H., Ishigami, C., Kaneko, J., Okuno, T., Takamatsu, H., Ito, D., Kang, S., Kimura, T., et al. (2013) · Nature Communications · doi:10.1038/ncomms2420 · Cited by 27
Tosi, J., Davis, R. J., Wang, N., Naumann, M. C., Lin, C., & Tsang, S. H. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01201.x · Cited by 29
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Manfredsson, F. P., Bloom, D. C., & Mandel, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.001 · Cited by 29
Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis
Stein, L., Roy, K., Lei, L., & Kaushal, S. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.557358 · Cited by 36
“[5,18,20,22] 12 of 12 (self-reported) 11 of 11 12 of 12 7 of 12 3 of 3 4 of 12 1 of 1 0”
BackgroundHNF-4α determines hepatic differentiation of human mesenchymal stem cells from bone marrow
Chen, M.-L., Lee, K.-D., Huang, H.-C., Tsai, Y.-L., Wu, Y.-C., Kuo, T.-M., Hu, C.-P., & Chang, C. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i40.5092 · Cited by 33
De Silva, S. R., Charbel Issa, P., Singh, M. S., Lipinski, D. M., Barnea-Cramer, A. O., Walker, N. J., Barnard, A. R., Hankins, M. W., & MacLaren, R. E. (2016) · Gene Therapy · doi:10.1038/gt.2016.54 · Cited by 29
“viral vectors (AAV2) have shown safety and efficacy (1-4).”
BackgroundPhotoreceptor Protection by Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF)
Lu, J., Luo, L., Huang, D., Liu, X., Xia, X., Wang, Z., Lam, B. L., Yi, J., Wen, R., & Li, Y. (2018) · eNeuro · doi:10.1523/eneuro.0109-18.2018 · Cited by 30
“The success of gene therapy for LCA2 proves that the function of RPE65 gene can be restored by introducing the normal RPE65 transgene into the retinal pigment epithelial (RPE) cells (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008).”
BackgroundKumaran, N., Rubin, G. S., Kalitzeos, A. A., Fujinami, K., Bainbridge, J. W., Weleber, R. G., & Michaelides, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-23873 · Cited by 31
Contribution of noncoding pathogenic variants to RPGRIP1-mediated inherited retinal degeneration
Jamshidi, F., Place, E., Mehrotra, S., Navarro-Gomez, D., Maher, M., Branham, K. E. H., Valkanas, E., Cherry, T. J., Lek, M., MacArthur, D. G., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0104-7 · Cited by 38
Self-citationYang, U., Gentleman, S., Gai, X., Gorin, M. B., Borchert, M., Lee, T. C., Villanueva, A., Koenekoop, R. K., Maguire, A. M., Bennett, J., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.3914 · Cited by 29
Self-citationTwo-Plasmid Packaging System for Recombinant Adeno-Associated Virus
Tang, Q., Keeler, A. M., Zhang, S., Su, Q., Lyu, Z., Cheng, Y., Gao, G., & Flotte, T. R. (2020) · BioResearch open access · doi:10.1089/biores.2020.0031 · Cited by 33
Stem Cells and Gene Therapy in Progressive Hearing Loss: the State of the Art
Nourbakhsh, A., Colbert, B., Nisenbaum, E., El-Amraoui, A., Dykxhoorn, D. M., Koehler, K. R., Chen, Z., & Liu, X. Z. (2021) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-020-00781-0 · Cited by 34
Waddington, S. N., Peranteau, W. H., Rahim, A. A., Boyle, A. K., Kurian, M. A., Gissen, P., Chan, J. K. Y., & David, A. L. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12659 · Cited by 31
“30,31 ADA-SCID was treated by ex vivo hematopoietic stem cell therapy 32 (this time without evidence of leukemia 26 ).”
MethodPreclinical and clinical progress in hemophilia gene therapy
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833cd4bd · Cited by 36
Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas
Barbian, H. J., Decker, J. M., Bibollet‐Ruche, F., Galimidi, R. P., West, A. P., Learn, G. H., Parrish, N. F., Iyer, S. S., Li, Y., Pace, C. S., et al. (2015) · mBio · doi:10.1128/mbio.00296-15 · Cited by 33
Expression of Wild-Type Rp1 Protein in Rp1 Knock-in Mice Rescues the Retinal Degeneration Phenotype
Liu, Q., Collin, R. W. J., Cremers, F. P. M., den Hollander, A. I., van den Born, L. I., & Pierce, E. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043251 · Cited by 35
Self-citationMarangoni, D., Wu, Z., Wiley, H. E., Zeiss, C. J., Vijayasarathy, C., Zeng, Y., Hiriyanna, S., Bush, R. A., Wei, L. L., Colosi, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.067 · Cited by 29
“Recently, the results from three separate clinical trials for Leber’s congenital amaurosis (LCA) showed the safety of AAV2 in human patients (Bainbridge et al. , 2008; Cideciyan et al. , 2008; Maguire et al. , 2008).”
Potential Therapeutic Agents Against Retinal Diseases Caused by Aberrant Metabolism of Retinoids
Liu, X., Chen, J., Liu, Z., Li, J., Yao, K., & Wu, Y. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18429 · Cited by 32
Leber congenital amaurosis, from darkness to light: An ode to Irene Maumenee
Coussa, R. G., López, I., & Koenekoop, R. K. (2017) · Ophthalmic Genetics · doi:10.1080/13816810.2016.1275021 · Cited by 38
“stable improvement in visual acuity, area of the visual field enlargement, and nystagmus.(72,73) It is worth mentioning that both studies used different adeno-associated virus vectors,”
BackgroundTiming of Antioxidant Gene Therapy: Implications for Treating Dry AMD
Biswal, M. R., Han, P., Zhu, P., Wang, Z., Li, H., Ildefonso, C. J., & Lewin, A. S. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21272 · Cited by 30
Park, T. K., Lee, S. H., Choi, J., Nah, S. K., Kim, H. J., Park, H. Y., Lee, H., Lee, S. H. S., & Park, K. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.05.012 · Cited by 28
Jönsson, F., & Kreppel, F. (2017) · Virus Genes · doi:10.1007/s11262-017-1498-z · Cited by 29
Gene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 29
Men, C. J., Bujakowska, K. M., Comander, J., Place, E., Bedoukian, E. C., Zhu, X., Leroy, B. P., Fulton, A. B., & Pierce, E. A. (2017) · PubMed Central · Cited by 35
Self-citationHuman L- and M-opsins restore M-cone function in a mouse model for human blue cone monochromacy.
Deng, W., Li, J., Zhu, P., Chiodo, V. A., Smith, W. C., Freedman, B., Baehr, W., Pang, J., & Hauswirth, W. W. (2018) · PubMed Central · Cited by 30
A New Generation of Gene Therapies as the Future of Wet AMD Treatment
Błasiak, J., Pawłowska, E., Ciupińska, J., Derwich, M., Szczepańska, J., & Kaarniranta, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042386 · Cited by 33
“…research groups reported a successful subretinal injection of an AAV-based expression vector carrying the retinoid isomerohydrolase RPE65 (retinal pigment epithelium-specific 65 KDa protein) gene to improve vision in individuals with inherited blindness (Leber’s congenital amaurosis) [9–11].”
BackgroundUsing Stem Cells to Model Diseases of the Outer Retina
Yvon, C., Ramsden, C. M., Lane, A., Powner, M. B., da Cruz, L., Coffey, P. J., & Carr, A. F. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.05.001 · Cited by 34
Lee, S. H., Yang, J. Y., Madrakhimov, S. B., Park, H. Y., Park, K., & Park, T. K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.008 · Cited by 29
Maurya, S., Mary, B., & Jayandharan, G. R. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.164 · Cited by 28
Clérin, E., Marussig, M., Sahel, J., & Léveillard, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051625 · Cited by 33
Yin, L., Keeler, G. D., Zhang, Y., Hoffman, B. E., Ling, C., Qing, K., & Srivastava, A. (2020) · Gene Therapy · doi:10.1038/s41434-020-0140-1 · Cited by 30
Validation of a Vision-Guided Mobility Assessment for RPE65 -Associated Retinal Dystrophy
Kumaran, N., Ali, R. R., Tyler, N., Bainbridge, J. W., Michaelides, M., & Rubin, G. S. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.10.5 · Cited by 32
A comparison of AAV-vector production methods for gene therapy and preclinical assessment
Davidsson, M., Negrini, M., Hauser, S., Svanbergsson, A., Lockowandt, M., Tomasello, G., Manfredsson, F. P., & Heuer, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-78521-w · Cited by 31
A reliable and feasible qPCR strategy for titrating AAV vectors
Wang, F., Cui, X., Wang, M., Xiao, W., & Xu, R. (2013) · Medical Science Monitor Basic Research · doi:10.12659/msmbr.883968 · Cited by 28
“The safe and long-term effective expression of AAV has been confirmed by Phase I trails [1, 2].”
Efficacious and Safe Tissue-Selective Controlled Gene Therapy Approaches for the Cornea
Mohan, R. R., Sinha, S., Tandon, A., Gupta, R., Tovey, J. C. K., & Sharma, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018771 · Cited by 28
“adult patients with Leber’s congenital amaurosis affirmed the promise of gene therapy to treat eye diseases and prevent blindness in humans [2,3].”
BackgroundA Microparticle/Hydrogel Combination Drug-Delivery System for Sustained Release of Retinoids
Gao, S.-Q., Maeda, T., Okano, K., & Palczewski, K. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10279 · Cited by 34
Regenerative nanomedicine and the treatment of degenerative retinal diseases
Zarbin, M. A., Montemagno, C. D., Leary, J. F., & Ritch, R. H. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.167 · Cited by 29
Beyond Humanism: Reflections on Trans- and Posthumanism
Sorgner, S. L. (2010) · Cited by 28
Course of Ocular Function in PRPF31 Retinitis Pigmentosa
Hafler, B. P., Comander, J., Weigel-DiFranco, C., Place, E., & Pierce, E. A. (2016) · Seminars in Ophthalmology · doi:10.3109/08820538.2015.1114856 · Cited by 28
“It is of interest to note that visual acuity is a sensitive parameter for the RPE65-related Leber Congenital Amaurosis clinical trial, in which vision is profoundly affected from an early age.(9)”
BackgroundSelf-citationTseng, Y.-S., Vliet, K. V., Rao, L., McKenna, R., Byrne, B. J., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virological Methods · doi:10.1016/j.jviromet.2016.07.009 · Cited by 28
“…deficiency (Pollack 2012), and numerous clinical trials are in progress for many other disease targets (Bainbridge et al. 2008; Brantly et al. 2009; Daniel Gaudet 2012; Ginn et al. 2013; Maguire et al. 2009; Maguire et al. 2008; Mendell et al. 2009; Smith et al. 2013; Wierzbicki et al. 2013).”
BackgroundGene editing prospects for treating inherited retinal diseases
Benati, D., Patrizi, C., & Recchia, A. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106473 · Cited by 31
Safety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates
Weed, L., Ammar, M. J., Zhou, S., Wei, Z., Serrano, L. W., Sun, J., Lee, V., Maguire, A. M., Bennett, J., & Aleman, T. S. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.011 · Cited by 27
“Of note, the procedure in patients, unlike in NHPs, is performed after a core vitrectomy, to prevent longterm complications, such as tractional retinal detachments.(12) The injection bleb in this patient covered the entire area of photoreceptor preservation on SD-OCT retinal thickness topography maps (Figure 5A).”
BackgroundMethodInfluentialSelf-citationTransduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection
Giove, T. J., Sena-Esteves, M., & Eldred, W. D. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.08.011 · Cited by 27
Lee, S., Kang, I. K., Kim, J. H., Jung, B. K., Park, K., Chang, H., Lee, J. Y., & Lee, H. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.2.14 · Cited by 27
Metadata
- Authors
- Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.-X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., & Bennett, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- University of Iowa (US)
- Veterans Health Administration (US)
- Children's Hospital of Pittsburgh (US)
- University of Oklahoma (US)
- National Eye Institute (US)
- ORCID
- Maguire, Albert M.
- Simonelli, Francesca
- Pierce, Eric A.
- Pugh, Edward N.
- Mingozzi, Federico
- Banfi, Sandro
- Testa, Francesco
- Surace, Enrico M.
- Rossi, Settimio
- Arruda, Valder R.
- Konkle, Barbara
- Stone, Edwin
- Sun, Junwei
- Hertle, Richard
- Ma, Jian-xing
- Redmond, T. Michael
- Zhu, Xiaosong
- Shindler, Kenneth S.
- Maguire, Maureen G.
- Wright, J. Fraser
- Volpe, Nicholas J.
- Auricchio, Alberto
- High, Katherine A.
- Bennett, Jean
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2240-2248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2829748
- OpenAlex
- W2137222303
- Cited by
- 2,145
- References
- 27
- Citations by year
- 2026: 38 · 2025: 68 · 2024: 51 · 2023: 66 · 2022: 79 · 2021: 110 · 2020: 96 · 2019: 98 · 2018: 118 · 2017: 144 · 2016: 124 · 2015: 172 · 2014: 152 · 2013: 155 · 2012: 158
- FWCI
- 70.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Eye Institute (EY10820, R01EY010820)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, adeno-associated virus vectors, retinal pigment epithelium, macular hole, visual acuity, retinal function, adverse events, inherited retinal degeneration
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Promoter Regions, Genetic, Reflex, Pupillary, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.